12
Participants
Start Date
September 18, 2020
Primary Completion Date
May 6, 2024
Study Completion Date
May 6, 2024
A-dopamine
"During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days."
optimized oral treatment
The patient will received his usual dopaminergic treatment.
Hopital Roger Salengro, CHU Lille, Lille
Collaborators (1)
InBrain Pharma
UNKNOWN
University Hospital, Lille
OTHER